Business Description
Kyntra Bio Inc., formerly FibroGen Inc., is a San Francisco-based biopharmaceutical company founded in 1993 that focuses on developing treatments for serious diseases with limited options. Its two main programs include FG-3246, an antibody-drug conjugate aimed at certain prostate and other cancers, and Roxadustat, a drug for anemia linked to chronic kidney disease and myelodysplastic syndromes that has completed late-stage clinical trials across the United States, Europe, and Japan. The company works alongside partners Astellas Pharma and AstraZeneca to advance these therapies toward patients.
